📊 CRVS Key Takeaways
Investment Thesis
Corvus Pharmaceuticals faces severe operational challenges with negative operating income of -$43.0M and negative free cash flow of -$33.0M despite minimal revenue generation, indicating the company is not yet generating sustainable commercial returns. With only $4.6M in cash against ongoing operating losses of $32.8M annually, the company has approximately 1.7 months of cash runway at current burn rates, creating critical liquidity concerns.
CRVS Strengths
- Strong balance sheet structure with debt-free capital (0.00x Debt/Equity ratio)
- Excellent current and quick ratios at 6.21x indicating short-term liquidity adequacy relative to current liabilities
- Modest total liabilities of $9.9M provides low financial obligation burden
CRVS Risks
- Critically low cash position of $4.6M with negative operating cash flow of -$32.8M creates severe liquidity crisis within 2 quarters
- No revenue generation (N/A reported) suggests pipeline-stage biotech with unproven commercialization capability
- Negative returns on equity (-25.0%) and assets (-21.5%) demonstrate value destruction and unprofitable operations
Key Metrics to Watch
- Monthly cash burn rate and remaining runway until capital exhaustion
- Revenue recognition and pipeline advancement toward commercial stage
- Operating cash flow trajectory and achievement of cash flow breakeven milestone
CRVS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.21x current ratio provides a solid financial cushion.
CRVS Profitability Ratios
CRVS vs Healthcare Sector
How Corvus Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CRVS Balance Sheet & Liquidity
CRVS 5-Year Financial Trend
5-Year Trend Summary: Corvus Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.56 indicates the company is currently unprofitable.
CRVS Growth Metrics (YoY)
CRVS Capital Allocation
CRVS SEC Filings
Access official SEC EDGAR filings for Corvus Pharmaceuticals, Inc. (CIK: 0001626971)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRVS
What is the AI rating for CRVS?
Corvus Pharmaceuticals, Inc. (CRVS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRVS's key strengths?
Strong balance sheet structure with debt-free capital (0.00x Debt/Equity ratio). Excellent current and quick ratios at 6.21x indicating short-term liquidity adequacy relative to current liabilities.
What are the risks of investing in CRVS?
Critically low cash position of $4.6M with negative operating cash flow of -$32.8M creates severe liquidity crisis within 2 quarters. No revenue generation (N/A reported) suggests pipeline-stage biotech with unproven commercialization capability.
What is CRVS's revenue and growth?
Corvus Pharmaceuticals, Inc. reported revenue of N/A.
Does CRVS pay dividends?
Corvus Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CRVS SEC filings?
Official SEC filings for Corvus Pharmaceuticals, Inc. (CIK: 0001626971) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRVS's EPS?
Corvus Pharmaceuticals, Inc. has a diluted EPS of $-0.53.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.